LeciaVSequistMD

Oncology • Boston, MA

Assistant Professor of Medicine, Massachusetts General Hospital

Join to view full profile

Dr. Sequist is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Sequist's full profile

Already have an account?

Office
55 Fruit Street Yaw 7b
Hematology/Oncology
Boston, MA 02114
Phone+1 617-724-4000

Fax+1 617-726-0453
Is this information wrong?

Education & Training

Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2002 - 2005
Brigham and Women's HospitalResidency, Internal Medicine, 1999 - 2002
Harvard Medical SchoolClass of 1999

Certifications & Licensure

MA State Medical License 2001 - 2026
ME State Medical License 2020 - 2021
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly, 2014

Clinical Trials

Gefitinib in Treating Patients With Previously Untreated Stage IIIB or Stage IV Non-Small Cell Lung Cancer Start of enrollment: 2005 Sep 01
Completed
Phase 2
Phase I/II Safety Study of IPI-504 in Relapsed/Refractory Stage IIIb, or Stage IV Non-small Cell Lung Cancer (NSCLC) Start of enrollment: 2007 Jan 01
Completed
Phase 1, Phase 2
Erlotinib in Patients With Resected, Early Stage NSCLC With Confirmed Mutations in the EGFR Start of enrollment: 2007 Dec 01
Completed
Phase 2
Cetuximab as Therapy for Recurrent Non-Small Cell Lung Cancer Patients Who Have Received Prior Therapy Start of enrollment: 2006 Sep 01
Terminated
Phase 2
Erlotinib With or Without Hydroxychloroquine in Chemo-Naive Advanced NSCLC and (EGFR) Mutations Start of enrollment: 2009 Oct 01
Active, not recruiting
Phase 2
Hydroxychloroquine With or Without Erlotinib in Advanced Non-small Cell Lung Cancer (NSCLC) Start of enrollment: 2007 Jul 01
Terminated
Phase 1
Biopsies of Cancer Patients for Tumor Molecular Characterization Start of enrollment: 2010 Feb 01
Completed
Understanding Mechanisms of Acquired Resistance to BIBW2992 Start of enrollment: 2011 Feb 01
Completed
Not Applicable
IPI-504 in NSCLC Patients With ALK Translocations Start of enrollment: 2010 Oct 01
Terminated
Phase 2
Tivantinib Plus Erlotinib Versus Placebo Plus Erlotinib for the Treatment of Non-squamous, Non-small-cell Lung Cancer Start of enrollment: 2011 Jan 11
Terminated
Phase 3
Afatinib With CT and RT for EGFR-Mutant NSCLC Start of enrollment: 2012 Apr 01
Recruiting
Phase 2
Adjuvant Afatinib in Stage I-III NSCLC With EGFR Mutation Start of enrollment: 2013 Jan 01
Active, not recruiting
Phase 2
Phase 2 Study of AUY922 in NSCLC Patients With Exon 20 Insertion Mutations in EGFR Start of enrollment: 2013 Jul 01
Completed
Phase 2
A Study of Emibetuzumab in Non Small Cell Lung Cancer (NSCLC) Participants Start of enrollment: 2013 Aug 01
Completed
Phase 2
A Study of TAS-120 in Patients With Advanced Solid Tumors Start of enrollment: 2014 Jul 21
Completed
Phase 1, Phase 2
A Phase I/II, Multicenter, Open-label Study of EGFRmut-TKI EGF816, Administered Orally in Adult Patients With EGFRmut Solid Malignancies Start of enrollment: 2014 Jun 06
Completed
Phase 1, Phase 2
Join now to see all

Publications & Presentations

PubMed

Therapy for Stage IV Non-Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2023.3.
Owen, D. H., Ishmael A Jaiyesimi, Natasha B Leighl, Nofisat Ismaila, Krishna Alluri, Narjust Florez, Shirish Gadgeel, Gregory Masters, Erin L Schenk, Bryan J Schneider...> ;Journal of Clinical Oncology. 2024 Apr 10
Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2023.3.
Owen, D. H., Ishmael A Jaiyesimi, Natasha B Leighl, Nofisat Ismaila, Krishna Alluri, Narjust Florez, Shirish Gadgeel, Gregory Masters, Erin L Schenk, Bryan J Schneider...> ;Journal of Clinical Oncology. 2024 Apr 10
Phase II Study of Osimertinib in Patients With Epidermal Growth Factor Receptor Mutations: Results From the NCI-MATCH ECOG-ACRIN (EAY131) Trial Subprotocol E.
Monica F Chen, Zihe Song, Helena A Yu, Lecia V Sequist, Christine M Lovly, Edith P Mitchell, Jeffrey A Moscow, Robert J Gray, Victoria Wang, Lisa M McShane, Larry V Ru...> ;JCO Precision Oncology. 2024 Apr 1
Pack-Year Smoking History: An Inadequate and Biased Measure to Determine Lung Cancer Screening Eligibility.
Alexandra L Potter, Nuo N Xu, Priyanka Senthil, Deepti Srinivasan, Hang Lee, Wei Zheng, Julie R Palmer, G Scott Gazelle, Lydia Chelala, Florian J Fintelmann, Lecia V S...> ;Journal of Clinical Oncology. 2024 Mar 27
Deploying blood-based cancer screening.
Micalizzi, D., Sequist, L., Haber, D.> ;Science. 2024 Jan 26
Twenty-year Progress in Lung Cancer Screening: A Marathon, Not a Sprint.
Lecia V Sequist, Coral Olazagasti> ;Radiology. 2023 Nov 1
3 citations
Artificial Intelligence and Machine Learning in Lung Cancer Screening.
Scott J Adams, Peter Mikhael, Jeremy Wohlwend, Regina Barzilay, Lecia V Sequist, Florian J Fintelmann> ;Thoracic Surgery Clinics. 2023 Nov 1
Role of sex in lung cancer risk prediction based on single low-dose chest computed tomography.
Judit Simon, Peter Mikhael, Ismail Tahir, Alexander Graur, Stefan Ringer, Amanda Fata, Yang Chi-Fu Jeffrey, Jo-Anne Shepard, Francine Jacobson, Regina Barzilay, Lecia ...> ;Scientific Reports. 2023 Oct 30
Improving Eligibility Criteria for Lung Cancer Screening-Promises, Challenges, and Unmet Needs.
Lecia V Sequist, Erica T Warner, Chi-Fu Jeffrey Yang> ;JAMA Oncology. 2023 Dec 1
1 citations
Lung Cancer in Women: The Past, Present, and Future.
Narjust Florez, Lauren Kiel, Ivy Riano, Shruti Patel, Natasha Dhawan, Ivy Franco, Ashley Odai-Afotey, Kelly Meza, Nishwant Swami, Jyoti Patel, Lecia V Sequist, Kathryn...> ;Clinical Lung Cancer. 2024 Jan 1
Germline mutations and developmental mosaicism underlying-mutant lung cancer.
Risa Burr, Ignaty Leshchiner, Christina L Costantino, Martin Blohmer, Tilak Sundaresan, Justin Cha, Karsen Seeger, Sara Guay, Brian P Danysh, Ira Gore, Raquel A Jacobs...> ;Medrxiv. 2023 Sep 29
3 citations
Efficacy and Tolerability of/Combinations in Patients With-Rearranged Lung Cancer With AcquiredAmplification: A Retrospective Analysis.
Ibiayi Dagogo-Jack, Lesli A Kiedrowski, Rebecca S Heist, Jessica J Lin, Catherine B Meador, Elizabeth A Krueger, Andrew Do, Jennifer Peterson, Lecia V Sequist, Justin ...> ;JTO Clinical and Research Reports. 2023 Aug 1
17 citations
Therapy-induced APOBEC3A drives evolution of persistent cancer cells.
Hideko Isozaki, Ramin Sakhtemani, Ammal Abbasi, Naveed Nikpour, Marcello Stanzione, Sunwoo Oh, Adam Langenbucher, Susanna Monroe, Wenjia Su, Heidie Frisco Cabanos, Far...> ;Nature. 2023 Aug 1
1 citations
B-Cell Infiltrate in the Tumor Microenvironment Is Associated With Improved Survival in Resected Lung Adenocarcinoma.
Ibiayi Dagogo-Jack, Ivan Valiev, Nikita Kotlov, Anna Belozerova, Aleksandra Lopareva, Anna Butusova, Naira Samarina, Alexandra Boyko, Zhongmin Xiang, Monique Johnson, ...> ;JTO Clinical and Research Reports. 2023 Jul 1
21 citations
Sybil: A Validated Deep Learning Model to Predict Future Lung Cancer Risk From a Single Low-Dose Chest Computed Tomography.
Peter G Mikhael, Jeremy Wohlwend, Adam Yala, Ludvig Karstens, Justin Xiang, Angelo K Takigami, Patrick P Bourgouin, PuiYee Chan, Sofiane Mrah, Wael Amayri, Yu-Hsiang J...> ;Journal of Clinical Oncology. 2023 Apr 20
4 citations
Expanding the Reach and Grasp of Lung Cancer Screening.
Raymond U Osarogiagbon, Pan-Chyr Yang, Lecia V Sequist> ;American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting. 2023 Jan 1
26 citations
Therapy for Stage IV Non-Small-Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2022.2.
Dwight H Owen, Navneet Singh, Nofisat Ismaila, Elizabeth Blanchard, Paul Celano, Narjust Florez, Dharamvir Jain, Natasha B Leighl, Hirva Mamdani, Gregory Masters, Pame...> ;Journal of Clinical Oncology. 2023 Feb 10
10 citations
Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2022.2.
Dwight H Owen, Navneet Singh, Nofisat Ismaila, Elizabeth Blanchard, Paul Celano, Narjust Florez, Dharamvir Jain, Natasha B Leighl, Hirva Mamdani, Gregory Masters, Pame...> ;Journal of Clinical Oncology. 2023 Feb 10
29 citations
Osimertinib + Savolitinib to Overcome Acquired MET-Mediated Resistance in Epidermal Growth Factor Receptor-Mutated, MET-Amplified Non-Small Cell Lung Cancer: TATTON.
Ryan J Hartmaier, Aleksandra A Markovets, Myung Ju Ahn, Lecia V Sequist, Ji-Youn Han, Byoung Chul Cho, Helena A Yu, Sang-We Kim, James Chih-Hsin Yang, Jong-Seok Lee, W...> ;Cancer Discovery. 2023 Jan 9
3 citations
Clinicopathologic Characteristics and Outcomes for Patients WithG12D-Mutant NSCLC.
Alona Muzikansky, Jochen Lennerz, Farhaana Narinesingh, Mari Mino-Kenudson, Yin P Hung, Zofia Piotrowska, Ibiayi Dagogo-Jack, Lecia V Sequist, Justin F Gainor, Jessica...> ;JTO Clinical and Research Reports. 2022 Sep 1
3 citations
Nazartinib for treatment-naive EGFR-mutant non-small cell lung cancer: Results of a phase 2, single-arm, open-label study.
Daniel S W Tan, Sang-We Kim, Santiago Ponce Aix, Lecia V Sequist, Egbert F Smit, James C H Yang, Toyoaki Hida, Ryo Toyozawa, Enriqueta Felip, Juergen Wolf, Christian G...> ;European Journal of Cancer. 2022 Sep 1
2 citations
Author Correction: Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management.
Alissa J Cooper, Lecia V Sequist, Jessica J Lin> ;Nature Reviews. Clinical Oncology. 2022 Nov 1
13 citations
High-Dose Osimertinib for CNS Progression in EGFR+ NSCLC: A Multi-Institutional Experience.
A J Piper-Vallillo, Julia K Rotow, Jacqueline V Aredo, Khvaramze Shaverdashvili, Jia Luo, Jennifer W Carlisle, Hatim Husain, Alona Muzikansky, Rebecca S Heist, Deepa R...> ;JTO Clinical and Research Reports. 2022 Jun 1
120 citations
Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management.
Alissa J Cooper, Lecia V Sequist, Jessica J Lin> ;Nature Reviews. Clinical Oncology. 2022 Aug 1
Phase II Study of Cabozantinib in Patients With Bone Metastasis.
Edwin Choy, Gregory M Cote, M Dror Michaelson, Lori Wirth, Justin F Gainor, Alona Muzikansky, Lecia V Sequist, Ryan J Sullivan, Panagiotis M Fidias, Alice Shaw, Rebecc...> ;The Oncologist. 2022 Jul 5
Join now to see all

Journal Articles

Oxford University Press Has Registered This DOI Pre-Publication
R S Heist, Z Piotrowska, C G Azzoli, A T Shaw, I T Lennes, L V Sequist, J F Gainor, Oxford University Press
EGFR Exon 20 Insertion Mutations Display Sensitivity to Hsp90 Inhibition in Preclinical Models and Lung Adenocarcinomas
Lecia V Sequist, Zofia Piotrowska, Clinical Cancer Research
A Digital RNA Signature of Circulating Tumor Cells Predicting Early Therapeutic Response in Localized and Metastatic Breast Cancer
David T Miyamoto, Aditya Bardia, Lecia V Sequist, Laura M Spring, Daniel A Haber, Mark Kalinich, Clinical Cancer Research
Stress Hormones Promote EGFR Inhibitor Resistance in NSCLC: Implications for Combinations with Β-blockers
Hai Tran, Anil K Sood, John V Heymach, Roy Herbst, Lecia V Sequist, Edward S Kim, Science Magazine
Join now to see all

Lectures

SHERLOC: A phase 2 study of MM-121 plus with docetaxel versus docetaxel alone in patients with heregulin (HRG) positive advanced non-small cell lung cancer (NSCLC).
2019 ASCO Annual Meeting - 6/1/2019
The ASCENT trial: A phase II study of neoadjuvant afatinib, chemoradiation and surgery for stage III EGFR mutation-positive NSCLC.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018

Other

Personalized, genotype-directed therapy for advanced non-small cell lung cancer
Sequist LV, Neal JW
http://www.uptodate.com/contents/personalized-genotype-directed-therapy-for-advanced-non-small-cell-
UpToDate, Wolters Kluwer Health - 2013-02-25

Press Mentions

Promising New AI Can Detect Early Signs of Lung Cancer That Doctors Can't SeeApril 11th, 2023
AI Tool Forecasts Lung Cancer Risk from a Single CT ScanFebruary 7th, 2023
This Software Tries to Spot Lung Cancer Years Earlier. Can It?February 1st, 2023
Join now to see all